Initiative

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

Nano Dimension Announces Record 2023 Revenue of $56.3 Million and Organic Growth of 29%

Retrieved on: 
Thursday, March 21, 2024
Research, Service provider, Attention, ROI, Senior, RET, Tower Semiconductor, Initiative, AME, Share repurchase, Sale, 3D, Acquisition, G&A, Aviation, Multi, ADS, Record, Nano, Robotics, Annual general meeting, PCB, Vice president, Workforce, Patent, 3D printing, Fraunhofer Society, Marketing, Corporate development, Human, Army, Printing, Video game

WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”), today announced financial results for the fourth quarter and full year ended December 31st, 2023.

Key Points: 
  • Nano Dimension has a breadth of technologies and products assortment, yet narrow and focused span of synergistic vertical markets.
  • It is specifically designed to enable Nano Dimension to become operating income positive in 2025, and potentially cash flow positive earlier.
  • As an example, Q4/2023’s $14.5 million in revenue was 19% higher than the same period in the year before.
  • With close to $56.3 million of revenue, Nano Dimension is the fastest growing of the cohort of publicly traded AM / 3D printing companies (approximately 10-12).

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Tuesday, March 19, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Patient, City University, Journal, Biomarker, News, LLP, Scientific misconduct, Neurobiology of Aging, Cognition, Safety, Advertising, Data management, FDA, Court, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 18, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Friday, March 15, 2024
Cassava Sciences, Initiative, Science, District court, Patient, City University, Journal, Biomarker, News, Ext, LLP, Cassava, Complaint, Person, Neurobiology of Aging, Cognition, Safety, Pomerantz, Action Replay, Data management, FDA, Court, Pharmaceutical industry

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Thursday, March 14, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Patient, City University, Journal, Biomarker, News, LLP, Scientific misconduct, Neurobiology of Aging, Cognition, Safety, Advertising, Data management, FDA, Court, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 13, 2024
Apoptosis, Patient, AMX0035, Science, P.C, Prospectus, Initiative, Form, Public expenditure, Scientific misconduct, IBD, Graphite, Safety, Data management, EAF, Reuters, Register, Food, Cassava Sciences, ALS, Alzheimer's disease, Uber, Defendant, Journal, Amyotrophy, News, Prescription, IPO, Particulates, Amylyx Pharmaceuticals, FDA, Sustainable development, DoorDash, Health, Environment, City University, Biomarker, Electrode, Cassava, Complaint, GrafTech, Investor's Business Daily, Neurobiology of Aging, Cognition, Government, BBC World Service, Evercore, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

Retrieved on: 
Thursday, April 4, 2024
Data Management, Biotechnology, Technology, FDA, Health, Pharmaceutical, Health Technology, Research, Software, Artificial Intelligence, Science, Simulations Plus, Pharmacology, QST, Initiative, Partnership, Risk, QSP, SLP, Safety, Toxicology, Liver, Hepatotoxicity, Pharmaceutical industry

Dr. Paul B. Watkins, chair of the Scientific Advisory Board of the DILI-sim Initiative, said, “It is now known what properties to avoid to minimize liver toxicity in a new drug candidate -- but these same properties are often necessary to have therapeutic efficacy. By predicting safe dosing regimens of such drugs, DILIsym is now enabling successful development of important therapies that might otherwise be abandoned.”

Key Points: 
  • DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI).
  • The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions.
  • It also allows the FDA to evaluate the potential DILI risk across multiple populations, which supports informed decision-making regarding drug approvals.
  • Companies interested in a free trial version of the DILIsym software can request it here .

Rocket Lab Prepares to Launch Mission for KAIST and NASA to Deploy Satellites to Two Separate Orbits

Retrieved on: 
Monday, April 1, 2024
Other Transport, Technology, Transport, Satellite, Other Technology, Aerospace, Manufacturing, Other Science, Science, Neutron, Artificial intelligence, Wind, Spacecraft, ICT, Electron, Asteroid, Burns, Initiative, Varda, Lab, Curie, NASA, Sunlight, Rocket Lab, Ministry, Kick, MSIT, Security (finance), Annual report, Engineering, Pressure, Silicon, Moon, Satrec Initiative, Korea Aerospace Research Institute, Communications satellite

Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced it has set the launch window for its next Electron launch.

Key Points: 
  • Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced it has set the launch window for its next Electron launch.
  • The ‘Beginning Of The Swarm’ mission is scheduled to launch from Rocket Lab Launch Complex 1 in Mahia, New Zealand during a 14-day launch window that opens on April 24th.
  • The capability of Electron’s Kick Stage to perform multiple engine burns in space and deploy individual satellites to unique orbits is critical to this mission.
  • Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia.

Oasis Announces Third Year of Support for Japanese Women to Receive Director Training, in Cooperation with BDTI of Japan

Retrieved on: 
Monday, April 1, 2024
Professional Services, Education, Business, Consumer, Women, Training, Initiative, Q&A, Case study, CFO, Oasis, ESG, Strategic planning, Female, Interview, D&O, Financial regulation, Bank statement, Woman, Boot camp, P&L, Corporate law, CFA, Person, CCC, CPA, Nursing

For the third year in a row, Oasis Management Company Ltd. (“Oasis”) will support director training for women in Japan at the Board Director Training Institute of Japan (“BDTI”).

Key Points: 
  • For the third year in a row, Oasis Management Company Ltd. (“Oasis”) will support director training for women in Japan at the Board Director Training Institute of Japan (“BDTI”).
  • Oasis will pay all costs for qualified women who enroll by the end of June to take any of BDTI’s director training courses described below.
  • BDTI Representative Director Nicholas Benes said, “In previous years, so many qualified women applied that we scheduled additional dates for more programs.
  • BDTI also packages its e-learning modules with this course, for Japanese speakers.